Subsequent Events

3 Months Ended

Mar. 31, 2016

Subsequent Events [Abstract]

Subsequent Events

Subsequent Events

On May 9, 2016, the Company entered into a purchase and sale agreement pursuant to which the Company agreed to sell to Chiesi USA, Inc. and its parent company, Chiesi Farmaceutici S.p.A., substantially all of its assets relating to Cleviprex, Kengreal and Argatroban for Injection for an upfront payment equal to approximately $260.0 million payable at the closing of the transaction, subject to certain post-closing adjustments, and potential milestone payments of up to $480.0 million following achievement of specified U.S. net sales milestones with respect to Cleviprex and Kengreal. The closing of the transaction is subject to the satisfaction or waiver of customary conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.  The purchase and sale agreement contains representations, warranties and covenants as to the parties’ business, financial and legal obligations and provides for indemnification by each of the parties in certain circumstances and subject to certain limitations.